DPP-4抑制剂与糖尿病合并AD相关认知障碍患者的淀粉样蛋白负荷及认知结局的关联
该研究回顾性纳入282例18F-florbetaben淀粉样PET阳性的AD相关认知障碍(ADCI)患者,按糖尿病及DPP-4i使用分为三组。结果显示,使用DPP-4i的糖尿病ADCI患者整体及颞顶叶淀粉样蛋白负荷低于未使用DPP-4i的糖尿病ADCI患者和非糖尿病ADCI患者,且纵向MMSE及记忆回忆分下降更慢。提示DPP-4i使用与低淀粉样负荷及较好长期认知结局相关。
要点
- DPP-4i使用与糖尿病ADCI患者整体及颞顶叶淀粉样负荷更低相关。
- DPP-4i使用与纵向MMSE及记忆回忆分下降更慢相关。
- 该关联在调整年龄、性别、教育、认知状态及APOE ε4后仍显著。
核心结论
- DPP-4i使用与糖尿病ADCI患者低淀粉样负荷及较好长期认知结局相关。
研究设计与样本
- 回顾性研究纳入282例18F-florbetaben淀粉样PET阳性的ADCI患者。
- 按糖尿病及DPP-4i使用分为ADCI-DPP-4i+组(n=70)、ADCI-DPP-4i-组(n=71)和非糖尿病ADCI组(n=141)。
- 采用多重线性回归分析组间整体及区域淀粉样滞留差异,线性混合模型评估纵向MMSE变化。
主要发现
- ADCI-DPP-4i+组整体淀粉样负荷低于ADCI-DPP-4i-组(β=0.075, SE=0.024, p=0.002)。
- ADCI-DPP-4i+组整体淀粉样负荷低于非糖尿病ADCI组(β=0.054, SE=0.021, p=0.010)。
- ADCI-DPP-4i+组颞顶叶区域淀粉样负荷低于ADCI-DPP-4i-组和非糖尿病ADCI组。
- ADCI-DPP-4i+组纵向MMSE下降慢于ADCI-DPP-4i-组(β=0.772, SE=0.272, p=0.005)。
- ADCI-DPP-4i+组记忆回忆分下降慢于ADCI-DPP-4i-组(β=0.291, SE=0.116, p=0.012)。
临床怎么用
- 对糖尿病合并ADCI患者,DPP-4i使用可能与较低淀粉样负荷和较好认知结局相关,但需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To investigate whether dipeptidyl peptidase-4 inhibitors (DPP-4i) have beneficial effects on amyloid aggregation and longitudinal cognitive outcome in diabetic Alzheimer disease-related cognitive impairment (ADCI). METHODS: We retrospectively reviewed 282 patients with ADCI with positive 18F-florbetaben amyloid PET images. Patients were classified into 3 groups according to prior diagnosis of diabetes and DPP-4i use: diabetic patients being treated with (ADCI-DPP-4i+, n = 70) or without DPP-4i (ADCI-DPP-4i-, n = 71) and nondiabetic patients (n = 141). Multiple linear regression analyses were performed to determine intergroup differences in global and regional amyloid retention using standardized uptake value ratios calculated from cortical areas. We assessed longitudinal changes in Mini-Mental State Examination (MMSE) score using a linear mixed model. RESULTS: The ADCI-DPP-4i+ group had lower global amyloid burden than the ADCI-DPP-4i- group (β = 0.075, SE = 0.024, p = 0.002) and the nondiabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status. The ADCI-DPP-4i+ group had lower regional amyloid burden in temporo-parietal areas than either the ADCI-DPP-4i- group or the nondiabetic ADCI group. The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005) and memory recall subscore (β = 0.291, SE = 0.116, p = 0.012) than the ADCI-DPP-4i- group. DISCUSSION: These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.
引用
- Jeong SH, Kim HR, Kim J, et al. Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology. 2021. PMID: 34380754. doi:10.1212/WNL.0000000000012534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。